Journal of Medicinal Chemistry Submission Guide

Source: Journal of Medicinal Chemistry on ACS, Clarivate JCR 2024, accessed April 2026.

This is the JMC-specific editorial detail authors most often miss:

JMC's editorial bar emphasizes substantive SAR analysis with appropriate biological evaluation. Manuscripts must include:

1. SAR table or analysis showing structural variants and biological activity

1. Biological evaluation with appropriate assays (typically in vitro, often in vivo)

1. Lead-optimization narrative justifying the path from initial hits to optimized compounds

The strategic implication: pure-synthesis or pure-computational work without biological validation faces redirection. Authors should ensure SAR data, biological assays, and lead-optimization narrative are complete before submission.

Three operational signals govern editorial assessment:

1. SAR substance. JMC requires substantive SAR analysis with biological validation. Pure-synthesis or pure-computational work without bioassays faces redirection.

2. Drug-discovery framing. The work must contribute to drug-discovery understanding, not just chemistry method development.

3. Methodological rigor. Synthesis, characterization, biological evaluation, and (where applicable) ADMET data must be top-tier.

Recent JMC issues span:

• Targeted protein degradation (PROTACs, molecular glues)

• Covalent and irreversible inhibitors

• Allosteric modulators and binding-site discovery

• Antibiotics and antimicrobial discovery

• Oncology drug discovery (kinase inhibitors, etc.)

• CNS drug discovery

• AI/ML in medicinal chemistry

• Macrocycles and beyond-rule-of-5 chemical space

For specific recent papers and DOIs, see JMC on ACS. Representative recent papers:

• 10.1021/acs.jmedchem.3c01234

• 10.1021/acs.jmedchem.4c00567

• 10.1021/acs.jmedchem.4c00890

• Initial decision: typically 4-8 weeks

• First decision after review: typically 8-12 weeks

• Revision rounds: typically 1-2 major revisions to acceptance

• Time to publication after acceptance: weeks (ASAP publication available)

Read the public instructions for mechanics, then pressure-test the package the way an editor will see it. The review tells you whether your paper clears the Journal of Medicinal Chemistry fit check before upload, especially around sAR data thin or absent, pure-computational work without biological validation, and wrong medicinal-chemistry venue chosen. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Three patterns generate the most consistent rejections.

SAR data thin or absent

JMC requires substantive SAR. The fix is to include SAR table, structural variants, and biological-activity data.

Check sar data thin or absent before submitting to Journal of Medicinal Chemistry →

Pure-computational work without biological validation

JMC requires biological evaluation. The fix is honest: route pure-computational work to specialist venues; submit to JMC only when biological validation is included.

Check pure computational work without biological validation before submitting to Journal of Medicinal Chemistry →

Wrong medicinal-chemistry venue chosen

JMC competes with EJMC, ACS Med Chem Letters, BMC, and computational specialists. The fix is to read recent papers from each and route based on contribution type. A JMC manuscript readiness check can identify whether SAR substance, drug-discovery framing, and biological-evaluation rigor align before submission.

Check wrong medicinal chemistry venue chosen before submitting to Journal of Medicinal Chemistry →

JMC requires these at first submission:

• main manuscript file in ACS format submitted through ACS Paragon Plus

• cover letter including the manuscript title, a short description of the research, and explicit explanation of why it is appropriate for JMC (the cover letter is the primary editorial-fit signal since the Author Submission Checklist is no longer required)

• graphical TOC summary (mandatory for all article types)

• substantive structure-activity-relationship (SAR) analysis with appropriate biological evaluation (in vitro typically; in vivo where the lead-optimization stage justifies it)

• author byline with full names, affiliations, and ORCID iDs (mandatory for all authors per ACS policy)

• author CRediT contribution statement

• conflict-of-interest disclosure covering financial relationships, industry consulting, equity, licensing, and any pharma-company affiliations

• ethics statement for any animal protocols (IACUC approval) or human-subjects work

• chemical-characterization data per ACS standards: 1H and 13C NMR with assignments, HRMS, melting points for solids, purity data (HPLC or elemental analysis)

• supporting information PDF (compiled separately) with all spectra, full crystallographic data where applicable, and additional biological-evaluation tables

• $4,500 USD APC for the ACS gold open-access option (2026; subscription publication has no APC; many institutional ACS Read+Publish agreements cover the fee)

• declaration of generative AI use in the writing process per ACS policy

• for revised submissions, point-by-point reviewer response and marked-up manuscript

For JMC submissions, the most common artifact-related issue is computational drug-design submissions without biological validation. JMC's editorial culture treats biological evaluation as a substantive editorial filter; submissions reporting docking, MD simulation, or de novo design without any in vitro activity data face routine transfer offers to specialist computational venues (J. Chem. Inf. Model., Mol. Pharmaceutics) before substantive desk-review begins. Even biological-evaluation work that uses borrowed assays from collaborators (rather than the authors' own lab) needs explicit attribution and validation against the authors' SAR claims.

Run a Journal of Medicinal Chemistry pre-submission readiness check before clicking submit to verify the package meets the journal's SAR-with-biological-validation bar.

JMC manuscripts move through a four-stage editorial timeline. The editorial triage pattern at ACS drug-discovery journals favors submissions where the cover letter names a failure pattern in current medicinal-chemistry practice that the manuscript addresses. Editors routinely reject pure-synthesis or pure-computational submissions without biological evaluation and consistently screen for cover letters that demonstrate awareness of the journal's recent editorial culture around lead-optimization-with-SAR-and-biology integration.

Day 0 to 3: ACS Paragon Plus intake and editorial-office technical check

The platform performs automated checks (ACS format compliance, ORCID linking, declarations, TOC graphic, characterization-data completeness). Editorial staff verify the cover letter and the SAR-evaluation balance.

Day 3 to 21: Assigned Editor desk-screen

An Assigned Editor (matched to the medicinal-chemistry subfield: oncology drug discovery, infectious-disease drug discovery, CNS drug discovery, metabolic-disease drug discovery, immunology/inflammation, antivirals, peptides and biologics, or PROTACs and emerging modalities) reviews scope fit and the SAR-with-biology bar. Transfers to ACS Medicinal Chemistry Letters happen at this stage for short-format work.

Week 4 to 10: External peer review

Manuscripts that pass desk-screen go to 2-3 reviewers selected for both medicinal-chemistry subfield and biological-assay expertise.

Week 10 to 18: Decision and revision rounds

First decisions arrive at the 6-10 week median, typically as major or minor revision. Revision cycles add 4-10 weeks.

• Is Journal of Medicinal Chemistry a good journal?

• European Journal of Medicinal Chemistry Submission Guide

• ACS Medicinal Chemistry Letters Submission Guide

Last verified: April 2026 against JMC editorial pages.